Fagron N.V.

Capital/Financing Update • Dec 22, 2014

Waregem (Belgium) / Rotterdam (The Netherlands)¹ , 22 December 2014 –Arseus is pleased to announce that it has successfully extended and amended its existing Revolving Credit Facility (RCF) originally scheduled to mature in July 2017. The financial covenant, which is based on net financial debt and recurring REBITDA, remains unchanged. This new multicurrency facility of € 220 million, which will mature in December 2019 and includes two additional one year extension options, is arranged through a syndicate of existing and new international banks. The new syndicate consists of ING (Coordinator), BNP Paribas, HSBC, KBC Bank, Fifth Third Bank and Commerzbank.

As announced earlier, the EGM of Arseus NV, held on 12 December 2014, approved the change of the company name from Arseus NV in Fagron NV. The company's listing on Euronext Brussels and Euronext Amsterdam will be changed to Fagron (new ticker symbol: FAGR) as of 1 January 2015.

Ger van Jeveren, CEO of Fagron: "Fagron's proven track record and successful global strategy have resulted in an increased business valuation of the group. Under the new facility, the terms and conditions have been significantly improved which match the new core business profile of the company and the sustainable performance of the Fagron group. The refinancing contributes to Fagron's objective to maintain a healthy capital structure and to support our buy-and-build strategy."

1/2

For further information: Marieke Palstra Director Investor Relations +31 88 33 11 213 marieke.palstra@arseus.com

1 This press release was sent out by Arseus NV and Arseus BV.

Arseus profile

Arseus is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Arseus consists of two divisions: Fagron and HL Technology. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals.

The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

In the event of any discrepancy between the Dutch translation and the original English version of this press release, the latter shall prevail.